profit from every $100 of sales.
$0$100
SNDL
$1.40-1.06% today
-21.3% in 1 year
1-year low $1.151-year high $2.21
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What SNDL sold, what it kept, and what it did with the cash.
Sales went from CA$712 million in 2022 to CA$946 million in 2025, with -CA$15.8 million of profit last year.
SalesProfit
SNDL handed back 26% of the cash it generated last year.
Buybacks CA$15M
Free cash flow 2025CA$58M
Bought back its own sharesCA$15M
Paid as dividends–
Cash vs. debtCA$252M vs. CA$170M
SNDL vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| SNDL | No profit yet | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 98.8× · Very expensive | ||
 Galderma Group | 88.6× · Very expensive | ||
 Teva Pharmaceutical Industries | 35.6× · Expensive |
AI analysis
An AI analyst reads SNDL's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of CAD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 712 | 909 | 920 | 946 | |
| 140 | 190 | 240 | 259 | |
| -61 | -100 | -34 | -4 | |
| -327 | -99 | -41 | 48 | |
| -335 | -173 | -95 | -16 | |
| -1.46 | -0.67 | -0.36 | -0.06 | |
| 19.7% | 20.9% | 26.1% | 27.3% | |
| -8.6% | -11.0% | -3.6% | -0.5% | |
| -47.1% | -19.0% | -10.3% | -1.7% |
Balance sheet
| In millions of CAD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 1,559 | 1,473 | 1,349 | 1,336 |
| Cash | 280 | 195 | 218 | 252 |
| Total debt | 170 | 167 | 152 | 170 |
| Total liabilities | 232 | 244 | 216 | 235 |
| 1,306 | 1,212 | 1,133 | 1,101 | |
| 230 | 259 | 264 | 258 | |
| -20.0% | -9.4% | -6.0% | -0.5% | |
| -25.6% | -14.2% | -8.4% | -1.4% |
Cash flow
| In millions of CAD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -7 | -17 | 55 | 71 | |
| 11 | 8 | 11 | 13 | |
| -18 | -25 | 44 | 58 | |
| Dividends paid | – | – | – | – |
| 13 | 2 | 13 | 15 | |
| 10 | 15 | 20 | 14 |
Valuation
- –
- –
- –
- 0.5×
- 0.5×
- 8.3×
- 8.4×
- 12.0%
- -3.3%
- 0.0%
Profitability
- 27.3%
- -0.5%
- -1.7%
- 5.3%
- -0.5%
- -12.1%
- -1.0%
- -0.8%
- -0.6%
- 0.0%
Growth
- +9.9%
- –
- +32.4%
- –
- +8.5%
Financial health
- -1.3×
- 0.15
- 12.8%
- -1.3×
- 4.84
- 3.25
- 0.71
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 36%of 948
Bottom 21%of 871
Bottom 45%of 868
Top 5%of 985
What analysts expect
- Average price target
- $3.95
- Range
- $3.25 – $5.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 29, 2026 | -0.03 | -0.03 | +0.0% |
| Mar 12, 2026 | 0.03 | 0.01 | +200.0% |
| Nov 4, 2025 | -0.04 | -0.00 | −11,011.1% |
| Jul 31, 2025 | 0.01 | -0.04 | +125.0% |
| May 1, 2025 | -0.04 | -0.06 | +33.3% |
| Mar 18, 2025 | -0.19 | -0.01 | −1,800.0% |
| Nov 5, 2024 | -0.05 | -0.04 | −40.0% |
| Aug 1, 2024 | -0.01 | -0.04 | +75.0% |
News
SNDL cuts over 30% workforce at Kelowna manufacturing facilitySeeking Alpha · Oct 27, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
42No pass
Benjamin Graham
72Pass
Philip Fisher
24No pass
Peter Lynch
48No pass
Joel Greenblatt
0No pass
Charlie Munger
24No pass
Terry Smith
22No pass
Questions about SNDL
Is SNDL a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the SNDL AI analysis
What does SNDL do?
SNDL Inc. engages in the production, distribution, and sale of cannabis products in Canada. The company operates through Cannabis Operations and Retail Operations segments. It is in Drug Manufacturers - Specialty & Generic.
Does SNDL pay a dividend?
No. SNDL does not pay a dividend at the moment; in 2025 it returned $15.3 million to shareholders by buying back its own shares.
Is SNDL stock halal?
Yes. SNDL passes our halal screen: its business is permitted and its debt is 0% of its market value, under the 30% limit. How we check
How has SNDL stock done over the past year?
Down 21.3% over the past twelve months, to $1.40. It traded between $1.15 and $2.21 and is 36.7% below its high.
Who are SNDL's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with SNDL's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.